Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2017-04-05 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2016年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as the "2016年度财务决算报告" which translates to "2016 Annual Financial Settlement Report". It contains detailed financial data including income, profit, assets, liabilities, equity, cash flow, and financial ratios for the full fiscal year 2016. It also references an audit report issued by an accounting firm with an unqualified opinion, which is typical for annual financial reports. The length of the document (6991 characters) and the detailed financial statements and analysis confirm it is a full annual financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2016
2017-04-05 Chinese
独立董事关于第二届董事会第十次会议相关事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors regarding their prior approval opinion on the proposal to reappoint the accounting firm for the 2017 audit. It references the audit firm and the audit engagement but does not contain any actual audit report, financial statements, or detailed audit results. The document is short (765 characters) and serves as an internal governance or procedural approval related to audit services rather than the audit report itself. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement related to audit engagement but not the audit report itself.
2017-04-05 Chinese
关于召开2016年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2016 Annual General Meeting (AGM) of 贝达药业股份有限公司, including the date, time, venue, voting procedures (both in-person and online), agenda items to be discussed and voted on, and instructions for shareholders. It includes information about the meeting logistics, registration, proxy voting, and the agenda which covers reports such as the 2016 Board of Directors report, Supervisory Board report, financial statements, profit distribution plan, and other proposals. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or notices about the AGM itself. The document length is over 6,000 characters and is comprehensive in describing the AGM arrangements, but it is not the annual report or financial statements themselves. Therefore, the correct classification is AGM Information (AGM-R).
2017-04-05 Chinese
中国国际金融股份有限公司关于公司2016年度现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2016年度现场检查报告" (2016 Annual On-site Inspection Report) by China International Capital Corporation Limited regarding Betta Pharmaceuticals Co., Ltd. It details a comprehensive on-site inspection covering governance, internal control, information disclosure, use of raised funds, performance, and other important matters for the year 2016. The content includes detailed compliance checks, internal audit evaluations, and confirmation of no issues requiring rectification. This is a standalone audit or inspection report focusing on regulatory compliance and internal controls rather than a full annual report or financial statements. It is not an announcement or a brief summary but a detailed inspection report. Therefore, it fits best under the category Audit Report / Information (AR). FY 2016
2017-04-05 Chinese
2016年度董事会工作报告
Board/Management Information Classification · 95% confidence The document is titled '2016 年度董事会工作报告' which translates to '2016 Annual Board of Directors Work Report'. It contains detailed information about the company's board activities, including the number of board meetings held, resolutions passed, committee activities, governance practices, and strategic outlook. It also includes financial performance summaries and operational highlights for the year 2016. The document is lengthy (over 14,000 characters) and contains substantive content about the board's work and company governance rather than just an announcement or summary. This matches the description of 'Board/Management Information (MANG)', which covers announcements of changes or reports related to the company's board or senior management. It is not an Annual Report (10-K) because it lacks comprehensive financial statements and full financial performance details; it is not an Audit Report (AR) because it is not a standalone audit report; it is not a Call Transcript (CT) or Earnings Release (ER) as it is not a transcript or a brief financial result announcement. The document focuses on the board's work and governance activities, fitting best under MANG.
2017-04-05 Chinese
2016年度独立董事述职报告（赵骏）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's 2016 Annual Report" for Betta Pharmaceuticals Co., Ltd. It details the independent director's activities, attendance at board and shareholder meetings, opinions on various board resolutions, committee work, protection of investor rights, and training during the year 2016. The content focuses on the director's duties and oversight rather than presenting financial statements or audit results. It is a report by an independent director on their performance and responsibilities during the year, which aligns with Board/Management Information filings. The document length is 2717 characters, which is relatively short and focused on director duties rather than a full annual report or audit report. Therefore, the best fitting category is Board/Management Information (MANG).
2017-04-05 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.